These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

651 related items for PubMed ID: 32970925

  • 1. Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease.
    Schmidt A, Anton A, Shapiro J, Wong S, Azad A, Kwan E, Spain L, Muthusamy A, Torres J, Parente P, Parnis F, Goh J, Joshua AM, Pook D, Gibbs P, Tran B, Weickhardt A.
    Asia Pac J Clin Oncol; 2021 Feb; 17(1):36-42. PubMed ID: 32970925
    [Abstract] [Full Text] [Related]

  • 2. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [Abstract] [Full Text] [Related]

  • 3. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
    Barata P, Emamekhoo H, Mendiratta P, Koshkin V, Tyler A, Ornstein M, Rini BI, Gilligan T, Kyriakopoulos C, Garcia JA.
    Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice.
    Park K, Kim JY, Park I, Shin SH, Lee HJ, Lee JL.
    Yonsei Med J; 2023 Feb; 64(2):86-93. PubMed ID: 36719015
    [Abstract] [Full Text] [Related]

  • 9. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate.
    Thomsen FB, Røder MA, Rathenborg P, Brasso K, Borre M, Iversen P.
    Scand J Urol; 2014 Jun; 48(3):268-75. PubMed ID: 24255983
    [Abstract] [Full Text] [Related]

  • 10. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of Urology.
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong Kong.
    Poon DMC, Wong KCW, Chan TW, Law K, Chan K, Lee EKC, Lee C, Chan M, Hong Kong Society of Uro-Oncology (HKSUO).
    Clin Genitourin Cancer; 2018 Oct; 16(5):402-412.e1. PubMed ID: 30126765
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study.
    Saad F, Hussain MHA, Tombal B, Fizazi K, Sternberg CN, Crawford ED, Nordquist LT, Bögemann M, Tutrone R, Shore ND, Belkoff L, Fralich T, Jhaveri J, Srinivasan S, Li R, Verholen F, Kuss I, Smith MR.
    Eur Urol; 2024 Oct; 86(4):329-339. PubMed ID: 38644146
    [Abstract] [Full Text] [Related]

  • 17. Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter?
    Andrews JR, Ahmed ME, Karnes RJ, Kwon E, Bryce AH.
    Prostate; 2020 Apr; 80(5):399-406. PubMed ID: 31943289
    [Abstract] [Full Text] [Related]

  • 18. Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy.
    Kim KB, Jo JK, Ahn S, Lee S, Jeong SJ, Hong SK, Byun SS, Lee SE.
    Korean J Urol; 2015 Aug; 56(8):580-6. PubMed ID: 26279827
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.